AGEN
AGEN clinical trials: AGENUS INC
Every trial on ClinicalTrials.gov where AGENUS INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 62
- Trials linked
- 31
- As lead sponsor
- 31
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
AGEN on the catalyst calendar · AGEN registry changes
- Primary completion Sep 2027Sponsor estimatePhase 2NCT05608044A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerAgenus Inc. · Metastatic Colorectal CancerActive, not recruitingAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT05572970Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)Agenus Inc. · CancerAvailableAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 27, 2026ActualPhase 2NCT05529316A Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaAgenus Inc. · Advanced MelanomaTerminatedAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 15, 2022ActualPhase 1/Phase 2NCT03495882A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion...Agenus Inc. · Cervical CancerCompletedAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 5, 2026ActualPhase 2NCT05630183A Study of Botensilimab in Participants With Metastatic Pancreatic CancerAgenus Inc. · Metastatic Pancreatic Ductal AdenocarcinomaCompletedAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT06751524Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory ApprovalAgenus Inc. · Colorectal Cancer (CRC)AvailableAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 26, 2025ActualPhase 2NCT03894215RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical CancerAgenus Inc. · Cervical CancerTerminatedAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 13, 2025ActualPhase 1NCT03860272Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerAgenus Inc. · Advanced CancerActive, not recruitingAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 11, 2023ActualPhase 1NCT05025085A Study Investigating AGEN1777 in Participants With Advanced Solid TumorsAgenus Inc. · Advanced CancerCompletedAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 15, 2022ActualPhase 1/Phase 2NCT03104699A Study of AGEN2034 in Advanced Tumors and Cervical CancerAgenus Inc. · Advanced CancerCompletedAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 23, 2024ActualPhase 1NCT05377528Study of AGEN1571 in Participants With Advanced Solid TumorsAgenus Inc. · Advanced Solid TumorCompletedAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 30, 2022ActualPhase 1/Phase 2NCT02694822AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With...Agenus Inc. · Advanced Solid CancersCompletedAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 22, 2024ActualPhase 1NCT04121676Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced CancerAgenus Inc. · Advanced CancerCompletedAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2024Sponsor estimatePhase 2NCT05033132A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical CancerAgenus Inc. · Cervical CancerWithdrawnAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2005ActualPhase 2NCT00081809A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent LymphomaAgenus Inc. · Lymphoma, FollicularCompletedAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 22, 2021ActualPhase 3NCT04943627Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)Agenus Inc. · Advanced CancerWithdrawnAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 8, 2021ActualPhase 1NCT04156100A Study in Subjects With Advanced Solid TumorsAgenus Inc. · Advanced Solid TumorTerminatedAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 13, 2021ActualPhase 2NCT04607200AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable AngiosarcomaAgenus Inc. · AngiosarcomaWithdrawnAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 3, 2021ActualPhase 1NCT03673020Phase 1a Study to Evaluate Immunogenicity of ASV®Agenus Inc. · Solid Tumor, AdultCompletedAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2013ActualPhase 2NCT01687595Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital HerpesAgenus Inc. · Herpes Simplex Type 2CompletedAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2012ActualPhase 2NCT01147536Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at...Agenus Inc. · Renal Cell CarcinomaTerminatedAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 1, 2018ActualPhase 2NCT03411473Study of AGEN1884 With Pembrolizumab in 1L NSCLCAgenus Inc. · NSCLC Stage IVTerminatedAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2018ActualPhase 1NCT02992977Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced CancerAgenus Inc. · Advanced CancerTerminatedAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2006ActualPhase 3NCT00126178Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney CancerAgenus Inc. · Kidney CancerTerminatedAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2005ActualPhase 2NCT00082459Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in...Agenus Inc. · Renal Cell CarcinomaTerminatedAGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 37 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner